{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:12:23Z","timestamp":1761948743302,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejps.2021.106000","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T02:13:53Z","timestamp":1631240033000},"page":"106000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle"],"prefix":"10.1016","volume":"167","author":[{"given":"Dan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenkai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoru","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guimin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.106000_bib0001","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/carcin\/bgt227","article-title":"Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer","volume":"34","author":"Awasthi","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejps.2021.106000_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm.4256","article-title":"Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors","volume":"23","author":"Davidson","year":"2017","journal-title":"Nat. Med."},{"year":"2004","series-title":"SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. Presented at the 27th Annual San Antonio Breast Cancer Symposium","author":"Desai","key":"10.1016\/j.ejps.2021.106000_bib0003"},{"key":"10.1016\/j.ejps.2021.106000_bib0004","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106000_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery-new applications on the horizon","volume":"157","author":"Elsadek","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.106000_bib0006","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/sj.bjc.6601318","article-title":"Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin\/lipiodol","volume":"89","author":"Fujiyama","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2021.106000_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2016.06.027","article-title":"Development and characterization of voriconazole loaded nanoparticles for parenteral delivery","volume":"510","author":"F\u00fcredi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106000_bib0008","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s11671-017-2206-6","article-title":"Resveratrol-loaded albumin nanoparticles with prolonged blood circulation and improved biocompatibility for highly effective targeted pancreatic tumor therapy","volume":"12","author":"Geng","year":"2017","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.ejps.2021.106000_bib0009","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.3748\/wjg.v23.i32.5875","article-title":"Nano albumin bound-paclitaxel in pancreatic cancer: current evidences and future directions","volume":"23","author":"Giordano","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2021.106000_bib0010","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.2147\/IJN.S166769","article-title":"Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression","volume":"13","author":"Guo","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2021.106000_bib0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcis.2017.07.047","article-title":"Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment","volume":"507","author":"Han","year":"2017","journal-title":"J. Colloid. Interface. Sci."},{"key":"10.1016\/j.ejps.2021.106000_bib0012","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.106000_bib0013","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/pharmaceutics12070604","article-title":"Protein-based nanoparticles as drug delivery systems","volume":"12","author":"Hong","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106000_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.106000_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00535-017-1374-6","article-title":"Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial","volume":"53","author":"Ikeda","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejps.2021.106000_bib0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2021.106000_bib0017","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1248\/bpb.23.637","article-title":"In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol","volume":"23","author":"Kishimoto","year":"2000","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2021.106000_bib0018","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/13543784.16.6.855","article-title":"DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials","volume":"16","author":"Kratz","year":"2007","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.ejps.2021.106000_bib0019","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.106000_bib0020","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1007\/s11095-012-0958-3","article-title":"Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery","volume":"30","author":"Kulkarni","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2021.106000_bib0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jconrel.2020.10.015","article-title":"Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells","volume":"329","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.106000_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.xphs.2015.10.026","article-title":"Preparation, characterization, and antitumor activities of miriplatin-loaded liposomes","volume":"105","author":"Liu","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106000_bib0023","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1039\/C7TB02902K","article-title":"Penetration and drug delivery of albumin nanoparticles into pancreatic multicellular tumor spheroids","volume":"5","author":"Lu","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejps.2021.106000_bib0024","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","article-title":"Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy","volume":"479","author":"Mehta","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106000_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2021.106000_bib0026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/B:DRUG.0000011793.72775.d1","article-title":"Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma","volume":"22","author":"Okusaka","year":"2004","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2021.106000_bib0027","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1021\/nn400450p","article-title":"Biodistribution of different sized nanoparticles assessed by positron emission tomography: a general strategy for direct activation of metal oxide particles","volume":"7","author":"P\u00e9rez-Campa\u00f1a","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejps.2021.106000_bib0028","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12032-018-1175-7","article-title":"Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience","volume":"35","author":"Quinton","year":"2018","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejps.2021.106000_bib0029","first-page":"686","article-title":"US Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane\u00ae) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer","volume":"14","author":"Saif","year":"2013","journal-title":"JOP"},{"key":"10.1016\/j.ejps.2021.106000_bib0030","first-page":"H246","article-title":"Gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis","volume":"262","author":"Schnitzer","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejps.2021.106000_bib0031","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.2147\/IJN.S141407","article-title":"Effect of inhibitors of endocytosis and NF-kB signal pathway on folate-conjugated nanoparticle endocytosis by rat Kupffer cells","volume":"12","author":"Tang","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2021.106000_bib0032","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2015.12.004","article-title":"Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having target ability to rheumatoid arthritis tissues","volume":"497","author":"Thao le","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106000_bib0033","doi-asserted-by":"crossref","first-page":"25968","DOI":"10.1074\/jbc.272.41.25968","article-title":"Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway","volume":"272","author":"Tiruppathi","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2021.106000_bib0034","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2013.12.009","article-title":"The development of orally administrable gemcitabine prodrugs with d-enantiomer amino acids: enhanced membrane permeability and enzymatic stability","volume":"86","author":"Tsume","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.106000_bib0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/mt.2009.281","article-title":"The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls","volume":"18","author":"Vercauteren","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejps.2021.106000_bib0036","doi-asserted-by":"crossref","first-page":"17405","DOI":"10.1021\/acsnano.0c07610","article-title":"Bioengineered human serum albumin fusion protein as target\/enzyme\/pH three-stage propulsive drug vehicle for tumor therapy","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejps.2021.106000_bib0037","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.2147\/IJN.S274289","article-title":"Endocytosis and organelle targeting of nanomedicines in cancer therapy","volume":"15","author":"Wang","year":"2020","journal-title":"Int. J. Nanomedicine."},{"key":"10.1016\/j.ejps.2021.106000_bib0038","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/nn9012274","article-title":"Size and dynamics of caveolae studied using nanoparticles in living endothelial cells","volume":"3","author":"Wang","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejps.2021.106000_bib0039","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2015.12.019","article-title":"Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel","volume":"83","author":"Yin","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106000_bib0040","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.1021\/acs.jmedchem.0c00950","article-title":"Platinum-based combination therapy: molecular rationale, current clinical uses, and future perspectives","volume":"63","author":"Yu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2021.106000_bib0041","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.2147\/IJN.S93835","article-title":"An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line","volume":"10","author":"Yu","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2021.106000_bib0042","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2021.106000_bib0043","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1177\/1535370215625473","article-title":"Preparation and evaluation of reduction-responsive nano-micelles for miriplatin delivery","volume":"241","author":"Zhang","year":"2016","journal-title":"Exp. Biol. Med (Maywood)"},{"key":"10.1016\/j.ejps.2021.106000_bib0044","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:58:36Z","timestamp":1760529516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721003031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"alternative-id":["S0928098721003031"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106000","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106000"}}